COMMUNIQUÉS West-GlobeNewswire

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
12/08/2025
MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with [...]
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
12/08/2025
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients [...]
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
12/08/2025
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $ [...]
NEXGEL Reports Second Quarter 2025 Financial Results
12/08/2025
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
12/08/2025
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD [...]
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for [...]
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
12/08/2025
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, [...]
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
12/08/2025
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million in cash, cash [...]
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
12/08/2025
Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than [...]
Iridex Reports Second Quarter 2025 Financial Results
12/08/2025
MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
12/08/2025
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
12/08/2025
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on [...]
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
12/08/2025
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation; incremental 6-month [...]
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase 2 Results of SLS009 in [...]
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
12/08/2025
-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
12/08/2025
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of [...]
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
12/08/2025
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. [...]

Pages